Imatinib mesylate: response in hypereosinophilic syndrome

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1381, 2003-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Imatinib mesylate promising for CML

By  

Inpharma, Vol. 1, Iss. 1303, 2001-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

A validated LC method for imatinib mesylate

By Vivekanand V.V.   Sreenivas Rao D.   Vaidyanathan G.   Sekhar N.M.   Avijit Kelkar S.   Ramachandra Puranik P.  

Journal of Pharmaceutical and Biomedical Analysis, Vol. 33, Iss. 5, 2003-12 ,pp. : 879-889

Elsevier

Access to resources Recommend Favorite

Imatinib Mesylate: A Viewpoint by Ian Judson

By Judson I.  

Drugs, Vol. 63, Iss. 5, 2003-01 ,pp. : 523-524

Adis International

Access to resources Recommend Favorite

Surpassing the success of imatinib mesylate in CML

By  

Inpharma, Vol. 1, Iss. 1385, 2003-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Lonafarnib overcomes imatinib mesylate resistance

By  

Inpharma, Vol. 1, Iss. 1357, 2002-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite